US biotech firm Moderna and Spanish laboratory Rovi announced a collaboration agreement to carry out the filling and finishing of a candidate vaccine for Covid-19 (mRNA-1273) outside the US. ROVI will carry out the phases of vial filling and completion. Thus it will acquire a new production line and the necessary equipment for formulation, filling, inspection and labelling, as well as the additional personnel required.The new line would be owned by Rovi, but Moderna will make the investment.
There has been a setback in the progress of a treatment to cure Covid-19. It was learned that remdesivir (Gilead’s antiviral) had not shown sufficient clinical improvement in the first clinical trial and even had important side effects. According to the company, these conclusions are associated with the trial that had to be stopped in China due to a lack of patients.